IBS Primary Logo Blue.png
Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
05 sept. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Science 37 Logo.jpg
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
06 août 2024 08h00 HE | Science 37, Inc.
Science 37 opens new, state-of-the-art facility, to enhance collaboration and improve patient recruitment and study support for clinical trials.
IBS Primary Logo Blue.png
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
01 août 2024 08h30 HE | Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions Inc. (INBS) partners with CenExel to perform a method comparison clinical study as part of the Company’s FDA clinical study plan.
IBS Logo Primary.jpg
Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success
18 juil. 2024 08h30 HE | Intelligent Bio Solutions, Inc.
NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Logo.png
Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe
23 juin 2023 08h01 HE | Ocean Biomedical, Inc.
Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...
Future Market Insights.png
Clinical Trials Market to Surpass US$ 177.7 Billion Valuation by 2033 Owing to the Development of Precision Medicines and Therapeutic Approaches | Future Market Insights, Inc. NEWARK, Del, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The global Clinical Trials Market is anticipated to augment at a flourishing CAGR of 4.41% over the forecast period from 2023 to 2033. The global...
Clinical ink Selecte
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
14 déc. 2022 10h47 HE | Clinical Ink
Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...
Featured Image for POP Biotechnologies
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
30 nov. 2022 15h01 HE | POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
AMR Logo.png
Patient Registry Software Market is Expected to Reach USD 2.50 Bn by 2031: Allied Market Research
10 oct. 2022 12h30 HE | Allied Market Research
Portland, OR, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the Global Patient Registry Software Market generated $993.3 million in 2021, and is...
EuCorVac-19
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
20 sept. 2022 21h31 HE | POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...